lorlatinib (BioDeep_00000797902)
代谢物信息卡片
lorlatinib
化学式: C21H19FN6O2 (406.1553446)
中文名称: 劳拉替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C
InChI: InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01ED - Anaplastic lymphoma kinase (alk) inhibitors
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C141136 - ALK Inhibitor
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:143117
- KEGGdrug: D11012
- PubChem: 71731823
- DrugBank: DB12130
- ChEMBL: CHEMBL3286830
- CAS: 1454846-35-5
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Yuyao Luo, Zhe Zhang, XuanZhu Guo, Xuemei Tang, Sijie Li, Guotao Gong, Shun Gao, Yan Zhang, Sheng Lin. Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis.
Lung cancer (Amsterdam, Netherlands).
2023 Aug; 184(?):107319. doi:
10.1016/j.lungcan.2023.107319. [PMID: 37597303] - Bei Zheng, Hong Jiang, Wenjuan Yang, Ying Li, Bingqing Liang, Jun Zhu, Nanmei Chen, Miao Chen, Meiling Zhang. A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer.
Cancer medicine.
2023 08; 12(15):15983-15997. doi:
10.1002/cam4.6241. [PMID: 37334877] - Benjamin J Solomon, Todd M Bauer, Tony S K Mok, Geoffrey Liu, Julien Mazieres, Filippo de Marinis, Yasushi Goto, Dong-Wan Kim, Yi-Long Wu, Jacek Jassem, Froylán López López, Ross A Soo, Alice T Shaw, Anna Polli, Rossella Messina, Laura Iadeluca, Francesca Toffalorio, Enriqueta Felip. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
The Lancet. Respiratory medicine.
2023 04; 11(4):354-366. doi:
10.1016/s2213-2600(22)00437-4. [PMID: 36535300] - Sara Verdura, José Antonio Encinar, Salvador Fernández-Arroyo, Jorge Joven, Elisabet Cuyàs, Joaquim Bosch-Barrera, Javier A Menendez. Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells.
International journal of molecular sciences.
2022 Sep; 23(17):. doi:
10.3390/ijms23179986. [PMID: 36077379] - Yoshiko Nakagawa, Tetsuo Shimizu, Hisato Hiranuma, Yasuhiro Gon. Successful treatment of refractory brain metastases from ALK-positive lung cancer with lorlatinib.
Thoracic cancer.
2022 05; 13(9):1431-1435. doi:
10.1111/1759-7714.14406. [PMID: 35373538] - Swan Lin, Jason Gong, George C Canas, Peter Winkle, Kathleen Pelletier, Robert R LaBadie, Katherine Ginman, Yazdi K Pithavala. A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment.
European journal of drug metabolism and pharmacokinetics.
2022 Mar; 47(2):235-245. doi:
10.1007/s13318-021-00747-4. [PMID: 35018553] - Jennifer E Hibma, Melissa O'Gorman, Sunil Nepal, Sylvester Pawlak, Katherine Ginman, Yazdi K Pithavala. Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.
Cancer chemotherapy and pharmacology.
2022 01; 89(1):71-81. doi:
10.1007/s00280-021-04368-1. [PMID: 34698901] - Katherine McGee, Neil J Stone, Shikha Wadhwani, Yashpal S Kanwar, Victoria Villaflor, Nausheen Akhter. A possible mechanism of hyperlipidemia in a patient with metastatic non-small cell lung cancer on lorlatinib therapy.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2021 Dec; 27(8):2010-2013. doi:
10.1177/10781552211004698. [PMID: 33789526] - Hao-Chuan Ma, Yi-Hong Liu, Kai-Lin Ding, Yu-Feng Liu, Wen-Jie Zhao, Yan-Juan Zhu, Xue-Song Chang, Ya-Dong Chen, Zhen-Zhen Xiao, Ya-Ya Yu, Rui Zhou, Hai-Bo Zhang. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
BMC cancer.
2021 Nov; 21(1):1278. doi:
10.1186/s12885-021-08977-0. [PMID: 34836510] - Huiping Xu, Melissa T O'Gorman, Sunil Nepal, Lee P James, Katherine Ginman, Yazdi K Pithavala. Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants.
Clinical pharmacology in drug development.
2021 11; 10(11):1395-1404. doi:
10.1002/cpdd.1000. [PMID: 34288547] - Joseph Chen, Ana Ruiz-Garcia, Leonard P James, Gerson Peltz, Holger Thurm, Jill Clancy, Jennifer Hibma. Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer.
Clinical pharmacology and therapeutics.
2021 11; 110(5):1273-1281. doi:
10.1002/cpt.2228. [PMID: 33973232] - Jerry Li, Yazdi K Pithavala, Jason Gong, Robert R LaBadie, Josué Kunjom Mfopou, Joseph Chen. The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants.
Clinical pharmacokinetics.
2021 10; 60(10):1303-1312. doi:
10.1007/s40262-021-01026-w. [PMID: 33937953] - Joseph Chen, Melissa T O'Gorman, Lee P James, Karen J Klamerus, Ganesh Mugundu, Yazdi K Pithavala. Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study.
Clinical pharmacokinetics.
2021 10; 60(10):1313-1324. doi:
10.1007/s40262-021-01015-z. [PMID: 33937954] - Chung-Shien Lee, Rimda Wanchoo, Nagashree Seetharamu. Lorlatinib induced proteinuria: A case report.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2021 Jun; 27(4):1037-1039. doi:
10.1177/1078155220961549. [PMID: 32996364] - Dongsheng Yue, Juanjuan Qian, Zhipeng Chen, Bin Zhang, Peng Chen, Lei Zhang, Jingjing Li, Henghui Zhang, Changli Wang. Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma.
Journal for immunotherapy of cancer.
2021 02; 9(2):. doi:
10.1136/jitc-2020-001967. [PMID: 33558279] - Joseph Chen, Brett Houk, Yazdi K Pithavala, Ana Ruiz-Garcia. Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants.
CPT: pharmacometrics & systems pharmacology.
2021 02; 10(2):148-160. doi:
10.1002/psp4.12585. [PMID: 33449423] - G D Marijn Veerman, Peter de Bruijn, Anne-Marie C Dingemans, Ron H J Mathijssen, Stijn L W Koolen. To quantify the small-molecule kinase inhibitors ceritinib, dacomitinib, lorlatinib, and nintedanib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry.
Journal of pharmaceutical and biomedical analysis.
2021 Jan; 193(?):113733. doi:
10.1016/j.jpba.2020.113733. [PMID: 33217707] - Alice T Shaw, Todd M Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres, Dong-Wan Kim, Tony Mok, Anna Polli, Holger Thurm, Anna M Calella, Gerson Peltz, Benjamin J Solomon. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
The New England journal of medicine.
2020 11; 383(21):2018-2029. doi:
10.1056/nejmoa2027187. [PMID: 33207094] - Han Hsi Wong, Helen Bentley, Venkata Ramesh Bulusu, Gloria Anyaegbu, James Watkins, Gail Horan, Helen Hatcher. Lorlatinib for the treatment of inflammatory myofibroblastic tumour with TPM4-ALK fusion following failure of entrectinib.
Anti-cancer drugs.
2020 11; 31(10):1106-1110. doi:
10.1097/cad.0000000000000994. [PMID: 32868646] - Xiaoyun Lu, Jeff B Smaill, Ke Ding. Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.
Journal of medicinal chemistry.
2020 10; 63(19):10726-10741. doi:
10.1021/acs.jmedchem.0c00507. [PMID: 32432477] - Daria Stypinski, Luke Fostvedt, Justine L Lam, Alfin Vaz, Theodore R Johnson, Jan S Boerma, Yazdi K Pithavala. Metabolism, Excretion, and Pharmacokinetics of Lorlatinib (PF-06463922) and Evaluation of the Impact of Radiolabel Position and Other Factors on Comparability of Data Across 2 ADME Studies.
Journal of clinical pharmacology.
2020 09; 60(9):1254-1267. doi:
10.1002/jcph.1621. [PMID: 32441835] - Jing Yan, Xijian Zhou, Dejian Pan. A case of one lung adenocarcinoma patient harboring a novel FAM179A-ALK (F1, A19) rearrangement responding to lorlatinib treatment.
Lung cancer (Amsterdam, Netherlands).
2020 09; 147(?):26-29. doi:
10.1016/j.lungcan.2020.06.026. [PMID: 32652371] - Ibiayi Dagogo-Jack, Satoshi Yoda, Jochen K Lennerz, Adam Langenbucher, Jessica J Lin, Marguerite M Rooney, Kylie Prutisto-Chang, Audris Oh, Nathaniel A Adams, Beow Y Yeap, Emily Chin, Andrew Do, Hetal D Marble, Sara E Stevens, Subba R Digumarthy, Ashish Saxena, Rebecca J Nagy, Cyril H Benes, Christopher G Azzoli, Michael S Lawrence, Justin F Gainor, Alice T Shaw, Aaron N Hata. MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020 06; 26(11):2535-2545. doi:
10.1158/1078-0432.ccr-19-3906. [PMID: 32086345] - Maulik Patel, Joseph Chen, Stephanie McGrory, Melissa O'Gorman, Sunil Nepal, Katherine Ginman, Yazdi K Pithavala. The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants.
Investigational new drugs.
2020 02; 38(1):131-139. doi:
10.1007/s10637-019-00872-7. [PMID: 31728714] - Joseph Chen, Huiping Xu, Sylvester Pawlak, Leonard P James, Gerson Peltz, Kimberly Lee, Katherine Ginman, Michelle Bergeron, Yazdi K Pithavala. The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants.
Advances in therapy.
2020 02; 37(2):745-758. doi:
10.1007/s12325-019-01198-9. [PMID: 31863284] - Jia Hu, Baoshi Zhang, Fangfang Yao, Yan Fu, Dianjun Chen, Donghui Li, Nan Du, Analyn Lizaso, Jinlei Song, Lu Zhang, Xiaosong Li. Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.
Therapeutic advances in respiratory disease.
2020 Jan; 14(?):1753466620935770. doi:
10.1177/1753466620935770. [PMID: 32600123] - Go Makimoto, Kadoaki Ohashi, Shuta Tomida, Kazuya Nishii, Takehiro Matsubara, Hiroe Kayatani, Hisao Higo, Kiichiro Ninomiya, Akiko Sato, Hiromi Watanabe, Hirohisa Kano, Takashi Ninomiya, Toshio Kubo, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Shinichi Toyooka, Minoru Takata, Yoshinobu Maeda, Katsuyuki Kiura. Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2019 11; 14(11):2009-2018. doi:
10.1016/j.jtho.2019.07.017. [PMID: 31374369] - Todd M Bauer, Enriqueta Felip, Benjamin J Solomon, Holger Thurm, Gerson Peltz, Marc D Chioda, Alice T Shaw. Clinical Management of Adverse Events Associated with Lorlatinib.
The oncologist.
2019 08; 24(8):1103-1110. doi:
10.1634/theoncologist.2018-0380. [PMID: 30890623] - Alice T Shaw, Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Chia-Chi Lin, Ross A Soo, Gregory J Riely, Sai-Hong Ignatius Ou, Jill S Clancy, Sherry Li, Antonello Abbattista, Holger Thurm, Miyako Satouchi, D Ross Camidge, Steven Kao, Rita Chiari, Shirish M Gadgeel, Enriqueta Felip, Jean-François Martini. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2019 06; 37(16):1370-1379. doi:
10.1200/jco.18.02236. [PMID: 30892989] - Wenlong Li, Rolf W Sparidans, Yaogeng Wang, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel. Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
2019 Mar; 136(?):120-130. doi:
10.1016/j.ejpb.2019.01.016. [PMID: 30660696] - Rolf W Sparidans, Wenlong Li, Alfred H Schinkel, Jan H M Schellens, Jos H Beijnen. Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates.
Journal of pharmaceutical and biomedical analysis.
2018 Nov; 161(?):136-143. doi:
10.1016/j.jpba.2018.08.038. [PMID: 30149189] - Wenlong Li, Rolf W Sparidans, Yaogeng Wang, Maria C Lebre, Els Wagenaar, Jos H Beijnen, Alfred H Schinkel. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
International journal of cancer.
2018 10; 143(8):2029-2038. doi:
10.1002/ijc.31582. [PMID: 29744867] - Claudia Spatari, Wenlong Li, Alfred H Schinkel, Gaetano Ragno, Jan H M Schellens, Jos H Beijnen, Rolf W Sparidans. Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2018 Apr; 1083(?):204-208. doi:
10.1016/j.jchromb.2018.03.014. [PMID: 29550682] - Shinji Yamazaki, Justine L Lam, Helen Y Zou, Hui Wang, Tod Smeal, Paolo Vicini. Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.
The Journal of pharmacology and experimental therapeutics.
2014 Oct; 351(1):67-76. doi:
10.1124/jpet.114.217141. [PMID: 25073473]